UT-MD Anderson Cancer Center: Neoadjuvant Immunotherapy Improves Outlook In High-Risk Melanoma
March 02, 2023
March 02, 2023
HOUSTON, Texas, March 2 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on March 1, 2023:
* * *
Starting pembrolizumab before surgery instead of waiting until after surgery significantly improves the outlook for patients with stage III-IV melanoma
* * *
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue . . .
* * *
Starting pembrolizumab before surgery instead of waiting until after surgery significantly improves the outlook for patients with stage III-IV melanoma
* * *
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue . . .